<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39377297</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.3461</ELocationID><Abstract><AbstractText>There had been concerns about the acute complications during or shortly after coronavirus disease 2019 (COVID-19) treatment with nirmatrelvir/ritonavir (NMVr) and molnupiravir (MOL). This study aimed to compare the risks of selected acute safety events in patients treated with or without NMVr or MOL using the COVID-19 oral treatment safety assessment data, constructed through the linkage of nationwide databases: National COVID-19 registry, Real-time Prescription Surveillance, and National Health Insurance data. We identified all adults diagnosed with COVID-19 between January and November 2022, and then constructed two cohorts by matching up to four patients without antiviral treatment records to NMVr or MOL users using propensity score matching. Outcomes of interest were incident-selected cardiac (i.e., atrial fibrillation, other arrhythmia, bradycardia), neurological (i.e., seizure, neuropathy, encephalomyelitis), and miscellaneous (i.e., acute pancreatitis, acute liver injury, dysgeusia) events. A total of 739,935 NMVr users were matched with 2,951,690 comparators and 150,431 MOL users with 759,521 comparators. NMVr users were at lower risk for developing selected cardiac events (hazard ratio 0.74 [95% CI 0.65-0.87] for atrial fibrillation, 0.81 [0.65-0.99] for other arrhythmia, and 0.82 [0.70-0.96] for bradycardia) and dysgeusia (0.58 [0.45-0.74]). For MOL users, the risk was lower for atrial fibrillation (0.72 [0.53-0.96]) and dysgeusia (0.34 [0.18-0.65]). Overall, there were no increased risks of acute complications during and shortly after treatment with oral COVID-19 antivirals. Rather, the findings underscore their effectiveness in attenuating the risk of potential acute sequelae of COVID-19.</AbstractText><CopyrightInformation>© 2024 The Author(s). Clinical Pharmacology &amp; Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Ju Hwan</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-7253-6515</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Choi</LastName><ForeName>Ahhyung</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Gihwan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Eun-Jeong</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Min Joo</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huh</LastName><ForeName>Kyungmin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyungmin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Patient Management Team, Central Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunization, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungyeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Patient Management Team, Central Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Research, Center for Emerging Virus Research, National Institute of Infectious Disease, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-Hwi</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Patient Management Team, Central Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Min-Gyu</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Patient Management Team, Central Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Public Health Emergency Response Research, Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Il Uk</ForeName><Initials>IU</Initials><AffiliationInfo><Affiliation>Big Data Management Division, Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Poong Hoon</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Big Data Management Division, Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Geun Woo</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Big Data Management Division, Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hee Sun</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Big Data Management Division, Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Jaehun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ju-Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0003-1010-7525</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Design &amp; Evaluation, Samsung Advanced Institute for Health Sciences &amp; Technology (SAIHST), Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Korea Institute of Drug Safety and Risk Management</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39377297</ArticleId><ArticleId IdType="doi">10.1002/cpt.3461</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO Coronavirus (COVID‐19) dashboard &gt; Cases [Dashboard] &lt;https://data.who.int/dashboards/covid19/cases&gt; (2023).</Citation></Reference><Reference><Citation>Docherty, A.B. et al. Features of 20 133 UK patients in hospital with covid‐19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 369, m1985 (2020).</Citation></Reference><Reference><Citation>Ko, J.Y. et al. Risk factors for coronavirus disease 2019 (COVID‐19)‐associated hospitalization: COVID‐19‐associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin. Infect. Dis. 72, e695–e703 (2021).</Citation></Reference><Reference><Citation>US Food &amp; Drug Administration. FDA Approves First Oral Antiviral for Treatment of COVID‐19 in Adults &lt;https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐oral‐antiviral‐treatment‐covid‐19‐adults&gt; (2023).</Citation></Reference><Reference><Citation>UK Medicines and Healthcare products Regulatory Agency. First oral antiviral for COVID‐19, Lagevrio (molnupiravir), approved by MHRA [media release] &lt;https://www.gov.uk&gt; (2021).</Citation></Reference><Reference><Citation>Hammond, J. et al. Oral nirmatrelvir for high‐risk, nonhospitalized adults with Covid‐19. N. Engl. J. Med. 386, 1397–1408 (2022).</Citation></Reference><Reference><Citation>Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid‐19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2021).</Citation></Reference><Reference><Citation>Khoo, S.H. et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS‐CoV‐2 infection in the UK (AGILE CST‐2): a randomised, placebo‐controlled, double‐blind, phase 2 trial. Lancet Infect. Dis. 23, 183–195 (2023).</Citation></Reference><Reference><Citation>Najjar‐Debbiny, R. et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high‐risk patients. Clin. Infect. Dis. 76, e342–e349 (2022).</Citation></Reference><Reference><Citation>Wong, C.K.H., Au, I.C.H., Lau, K.T.K., Lau, E.H.Y., Cowling, B.J. &amp; Leung, G.M. Real‐world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in‐hospital outcomes among community‐dwelling, ambulatory patients with confirmed SARS‐CoV‐2 infection during the omicron wave in Hong Kong: an observational study. Lancet 400, 1213–1222 (2022).</Citation></Reference><Reference><Citation>Arbel, R. et al. Nirmatrelvir use and severe Covid‐19 outcomes during the omicron surge. N. Engl. J. Med. 387, 790–798 (2022).</Citation></Reference><Reference><Citation>Paraskevis, D. et al. Real‐world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID‐19 in patients at high risk. J. Infect. Dis. 228, 1667–1674 (2023).</Citation></Reference><Reference><Citation>DeMarco, E., Turnipseed, M., Clarke, B. &amp; Qadeer, F. Possible nirmatrelvir/ritonavir‐induced bradycardia in a patient with asymptomatic COVID‐19. SAGE Open Med. Case Rep. 11, 2050313x231168304 (2023).</Citation></Reference><Reference><Citation>Ganipisetti, V.M., Bollimunta, P. &amp; Maringanti, S. Paxlovid‐induced symptomatic bradycardia and syncope. Cureus 15, e33831 (2023).</Citation></Reference><Reference><Citation>Abi‐Saleh, S.P., Doumet, A.A. &amp; Ayyagari, R. S1769 Nirmatrelvir/ritonavir – a new culprit of acute pancreatitis. Am. J. Gastroenterol. 117, e1244–e1245 (2022).</Citation></Reference><Reference><Citation>Zaidi, S.M.H. et al. A rare case of Paxlovid‐induced pancreatitis. Cureus 15, e36528 (2023).</Citation></Reference><Reference><Citation>Yek, C. et al. Risk factors for severe COVID‐19 outcomes among persons aged ≥18 years who completed a primary COVID‐19 vaccination series – 465 health care facilities, United States, December 2020–October 2021. MMWR Morb. Mortal. Wkly Rep. 71, 19–25 (2022).</Citation></Reference><Reference><Citation>Charlson, M.E., Pompei, P., Ales, K.L. &amp; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).</Citation></Reference><Reference><Citation>Kim, J.M., Yoo, M.‐G., Bae, S.J., Kim, J. &amp; Lee, H. Effectiveness of Paxlovid, an oral antiviral drug, against the omicron BA.5 variant in Korea: severe progression and death between July and November 2022. J. Korean Med. Sci. 38, e211 (2023).</Citation></Reference><Reference><Citation>Haque, O.I., Mahar, S., Hussain, S. &amp; Sloane, P. Pharmacokinetic interaction between verapamil and ritonavir‐boosted nirmatrelvir: implications for the management of COVID‐19 in patients with hypertension. BMJ Case Rep. 16, e252677 (2023).</Citation></Reference><Reference><Citation>Zhuang, W. et al. Post‐marketing safety concerns with nirmatrelvir: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Br. J. Clin. Pharmacol. 89, 2830–2842 (2023).</Citation></Reference><Reference><Citation>Liang, Y., Ma, L., Wang, Y., Zheng, J., Su, L. &amp; Lyu, J. Adverse events associated with molnupiravir: a real‐world disproportionality analysis in Food and Drug Administration adverse event reporting system. Front. Pharmacol. 14, 1253799 (2023).</Citation></Reference><Reference><Citation>Shinozaki, S., Watanabe, A., Kimata, M., Miyazaki, M. &amp; Maekawa, S. Safety and effectiveness of molnupiravir in Japanese patients with COVID‐19: final report of post‐marketing surveillance in Japan. Infect. Dis. Ther. 13, 189–205 (2024).</Citation></Reference><Reference><Citation>Lechien, J.R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild‐to‐moderate forms of the coronavirus disease (COVID‐19): a multicenter European study. Eur. Arch. Otorhinolaryngol. 277, 2251–2261 (2020).</Citation></Reference><Reference><Citation>Tong, J.Y., Wong, A., Zhu, D., Fastenberg, J.H. &amp; Tham, T. The prevalence of olfactory and gustatory dysfunction in COVID‐19 patients: a systematic review and meta‐analysis. Otolaryngol. Head Neck Surg. 163, 3–11 (2020).</Citation></Reference><Reference><Citation>Xu, H. et al. High expression of ACE2 receptor of 2019‐nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 12, 8 (2020).</Citation></Reference><Reference><Citation>Caronia, L., Xi, R., Margolskee, R.F. &amp; Jiang, P. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir. Biochem. Biophys. Res. Commun. 682, 138–140 (2023).</Citation></Reference><Reference><Citation>Terzic, C.M. &amp; Medina‐Inojosa, B.J. Cardiovascular complications of coronavirus disease‐2019. Phys. Med. Rehabil. Clin. N. Am. 34, 551–561 (2023).</Citation></Reference><Reference><Citation>Soriano, J.B., Murthy, S., Marshall, J.C., Relan, P. &amp; Diaz, J.V. A clinical case definition of post‐COVID‐19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102–e107 (2022).</Citation></Reference><Reference><Citation>Jaffe, A.S., Cleland, J.G.F. &amp; Katus, H.A. Myocardial injury in severe COVID‐19 infection. Eur. Heart J. 41, 2080–2082 (2020).</Citation></Reference><Reference><Citation>Babapoor‐Farrokhran, S., Gill, D., Walker, J., Rasekhi, R.T., Bozorgnia, B. &amp; Amanullah, A. Myocardial injury and COVID‐19: possible mechanisms. Life Sci. 253, 117723 (2020).</Citation></Reference><Reference><Citation>Fung, K.W., Baye, F., Baik, S.H. &amp; McDonald, C.J. Nirmatrelvir and molnupiravir and post‐COVID‐19 condition in older patients. JAMA Intern. Med. 183, 1404–1406 (2023).</Citation></Reference><Reference><Citation>Xie, Y., Choi, T. &amp; Al‐Aly, Z. Association of treatment with nirmatrelvir and the risk of post–COVID‐19 condition. JAMA Intern. Med. 183, 554–564 (2023).</Citation></Reference><Reference><Citation>Xie, Y., Choi, T. &amp; Al‐Aly, Z. Molnupiravir and risk of post‐acute sequelae of covid‐19: cohort study. BMJ 381, e074572 (2023).</Citation></Reference><Reference><Citation>Kang, E., Lee, H., Hong, K.J., Yun, J., Lee, J.Y. &amp; Hong, Y.C. The general public's perspectives on telemedicine during the COVID‐19 pandemic in Korea: analysis of a nationwide survey. Epidemiol. Health 44, e2022020 (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>